Novartis (NVS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Novartis (NVS) reported $13.15 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 15.1%. EPS of $1.98 for the same period compares to $1.53 a year ago.The reported revenue represents a surprise of +1.44% over the Zacks Consensus Estimate of $12.97 billion. With the consensus EPS estimate being $1.81, the EPS surprise was +9.39%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Novartis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Hematology- Tasigna- US: $218 million versus $222.47 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -0.9% change. Net sales- Scemblix- Rest of world: $76 million versus the two-analyst average estimate of $80.45 million. Revenues- Hematology- Promacta/Revolade- US: $326 million versus the two-analyst average estimate of $291.70 million. The reported number represents a year-over-year change of +8.3%. Revenues- Immunology- Cosentyx- US: $1.01 billion versus the two-analyst average estimate of $1.03 billion. The reported number represents a year-over-year change of +36%. Revenues- Solid Tumors- Tafinlar + Mekinist- Total: $527 million versus the three-analyst average estimate of $521.97 million. The reported number represents a year-over-year change of +8.4%. Revenues- Net sales to third parties: $13.15 billion versus $12.85 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +15.1% change. Revenues- Solid Tumors- Kisqali- Total: $902 million compared to the $867.12 million average estimate based on three analysts. The reported number represents a change of +47.9% year over year. Revenues- Neuroscience- Gilenya- Total: $109 million compared to the $110.15 million average estimate based on three analysts. The reported number represents a change of -29.2% year over year. Revenues- Immunology- Cosentyx- Total: $1.60 billion versus $1.67 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +22.5% change. Revenues- Cardiovascular- Entresto- Total: $2.18 billion versus the three-analyst average estimate of $1.99 billion. The reported number represents a year-over-year change of +33.3%. Revenues- Established Brands- Galvus Group- Total: $144 million versus the three-analyst average estimate of $146.53 million. The reported number represents a year-over-year change of -5.9%. Revenues- Established Brands- Exforge Group- Total: $159 million compared to the $165.96 million average estimate based on three analysts. The reported number represents a change of +1.9% year over year. View all Key Company Metrics for Novartis here>>>Shares of Novartis have returned +7.8% over the past month versus the Zacks S&P 500 composite's +2.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks